{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Tucson&page=70&state=Arizona",
    "query": {
      "state": "Arizona",
      "city": "Tucson",
      "page": 70
    },
    "page_size": 10
  },
  "pagination": {
    "page": 70,
    "page_size": 10,
    "total_count": 5399,
    "total_pages": 540,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Tucson&page=71&state=Arizona&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Tucson&page=69&state=Arizona&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-09T22:37:36.857Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02176967",
      "title": "Response and Biology-Based Risk Factor-Guided Therapy in Treating Younger Patients With Non-high Risk Neuroblastoma",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Ganglioneuroblastoma",
        "Localized Resectable Neuroblastoma",
        "Localized Unresectable Neuroblastoma",
        "Neuroblastoma"
      ],
      "interventions": [
        {
          "name": "Biopsy Procedure",
          "type": "PROCEDURE"
        },
        {
          "name": "Bone Marrow Aspiration",
          "type": "PROCEDURE"
        },
        {
          "name": "Bone Marrow Biopsy",
          "type": "PROCEDURE"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Clinical Observation",
          "type": "OTHER"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Doxorubicin Hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Etoposide",
          "type": "DRUG"
        },
        {
          "name": "Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Ultrasound",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Children's Oncology Group",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "18 Months",
        "sex": "ALL",
        "summary": "Up to 18 Months"
      },
      "enrollment_count": 391,
      "start_date": "2014-08-08",
      "completion_date": "2027-10-06",
      "has_results": false,
      "last_update_posted_date": "2026-10-13",
      "last_synced_at": "2026-11-09T22:37:36.857Z",
      "location_count": 193,
      "location_summary": "Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 147 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Mesa",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02176967"
    },
    {
      "nct_id": "NCT06887192",
      "title": "A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Alzheimer's Disease Psychosis",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Psychosis Associated With Alzheimer's Disease"
      ],
      "interventions": [
        {
          "name": "ML-007C-MA",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "MapLight Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "55 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "55 Years to 90 Years"
      },
      "enrollment_count": 300,
      "start_date": "2025-08-15",
      "completion_date": "2027-12",
      "has_results": false,
      "last_update_posted_date": "2026-09-30",
      "last_synced_at": "2026-11-09T22:37:36.857Z",
      "location_count": 37,
      "location_summary": "Phoenix, Arizona • Scottsdale, Arizona • Tucson, Arizona + 30 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06887192"
    },
    {
      "nct_id": "NCT06203002",
      "title": "A Dose-ranging Study in Patients With Diabetic Peripheral Neuropathic Pain (DPNP)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Diabetic Peripheral Neuropathic Pain"
      ],
      "interventions": [
        {
          "name": "Placebo (blinded)",
          "type": "DRUG"
        },
        {
          "name": "LX9211 (blinded)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Lexicon Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 496,
      "start_date": "2023-11-29",
      "completion_date": "2025-02-24",
      "has_results": false,
      "last_update_posted_date": "2025-10-10",
      "last_synced_at": "2026-11-09T22:37:36.857Z",
      "location_count": 108,
      "location_summary": "Anniston, Alabama • Birmingham, Alabama • Daphne, Alabama + 91 more",
      "locations": [
        {
          "city": "Anniston",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Daphne",
          "state": "Alabama"
        },
        {
          "city": "Guntersville",
          "state": "Alabama"
        },
        {
          "city": "Chandler",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06203002"
    },
    {
      "nct_id": "NCT05633602",
      "title": "Ramucirumab Plus Pembrolizumab vs Usual Care for Treatment of Stage IV or Recurrent Non-Small Cell Lung Cancer Following Immunotherapy, Pragmatica-Lung Study",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Recurrent Lung Non-Small Cell Carcinoma",
        "Stage IV Lung Cancer AJCC v8"
      ],
      "interventions": [
        {
          "name": "Chemotherapy",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Ramucirumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "SWOG Cancer Research Network",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 838,
      "start_date": "2023-03-14",
      "completion_date": "2028-03-15",
      "has_results": false,
      "last_update_posted_date": "2026-04-17",
      "last_synced_at": "2026-11-09T22:37:36.857Z",
      "location_count": 566,
      "location_summary": "Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 442 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Fayetteville",
          "state": "Arkansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05633602"
    },
    {
      "nct_id": "NCT00864253",
      "title": "A Trial of ABI-007 Versus Dacarbazine in Previously Untreated Patients With Metastatic Malignant Melanoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Malignant Melanoma"
      ],
      "interventions": [
        {
          "name": "ABI-007",
          "type": "DRUG"
        },
        {
          "name": "Dacarbazine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Celgene",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 529,
      "start_date": "2009-04-23",
      "completion_date": "2014-02-12",
      "has_results": true,
      "last_update_posted_date": "2019-10-30",
      "last_synced_at": "2026-11-09T22:37:36.857Z",
      "location_count": 38,
      "location_summary": "Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 33 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Hot Springs",
          "state": "Arkansas"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00864253"
    },
    {
      "nct_id": "NCT02686762",
      "title": "Emricasan, a Caspase Inhibitor, for Evaluation in Subjects With Non-Alcoholic Steatohepatitis (NASH) Fibrosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Non-alcoholic Steatohepatitis",
        "Fibrosis",
        "Liver Diseases"
      ],
      "interventions": [
        {
          "name": "Emricasan (5 mg)",
          "type": "DRUG"
        },
        {
          "name": "Emricasan (50 mg)",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Conatus Pharmaceuticals Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 318,
      "start_date": "2016-01-26",
      "completion_date": "2019-02-28",
      "has_results": false,
      "last_update_posted_date": "2019-08-19",
      "last_synced_at": "2026-11-09T22:37:36.857Z",
      "location_count": 83,
      "location_summary": "Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 63 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Freestone",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02686762"
    },
    {
      "nct_id": "NCT02138786",
      "title": "Selinexor in Initial or Refractory and/or Relapsed Richter's Transformation",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Richter's Transformation"
      ],
      "interventions": [
        {
          "name": "selinexor",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Karyopharm Therapeutics Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 27,
      "start_date": "2014-11-14",
      "completion_date": "2016-08-31",
      "has_results": true,
      "last_update_posted_date": "2023-01-26",
      "last_synced_at": "2026-11-09T22:37:36.857Z",
      "location_count": 7,
      "location_summary": "Tucson, Arizona • Duarte, California • Santa Monica, California + 4 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02138786"
    },
    {
      "nct_id": "NCT00007605",
      "title": "Comparing the Effects of Amiodarone, Sotalol, and Placebo in Maintaining Sinus Rhythm in Patients With Atrial Fibrillation Converted to Sinus Rhythm",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Atrial Fibrillation",
        "Cerebrovascular Accident",
        "Death, Sudden"
      ],
      "interventions": [
        {
          "name": "Amiodarone",
          "type": "DRUG"
        },
        {
          "name": "Sotalol",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "US Department of Veterans Affairs",
      "sponsor_class": "FED",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 706,
      "start_date": "1998-04",
      "completion_date": "2003-12",
      "has_results": false,
      "last_update_posted_date": "2011-06-15",
      "last_synced_at": "2026-11-09T22:37:36.857Z",
      "location_count": 28,
      "location_summary": "Tucson, Arizona • No. Little Rock, Arkansas • Fresno, California + 25 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "No. Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Fresno",
          "state": "California"
        },
        {
          "city": "Loma Linda",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00007605"
    },
    {
      "nct_id": "NCT01073878",
      "title": "Athena Pelvic Muscle Trainer - DUETS Trial",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Urinary Incontinence"
      ],
      "interventions": [
        {
          "name": "Athena Pelvic Muscle Trainer",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Athena Feminine Technologies, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "30 Years",
        "maximum_age": "70 Years",
        "sex": "FEMALE",
        "summary": "30 Years to 70 Years · Female only"
      },
      "enrollment_count": 462,
      "start_date": "2010-02",
      "completion_date": "2011-06",
      "has_results": false,
      "last_update_posted_date": "2011-07-14",
      "last_synced_at": "2026-11-09T22:37:36.857Z",
      "location_count": 96,
      "location_summary": "Birmingham, Alabama • Dothan, Alabama • Casa Grande, Arizona + 87 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Dothan",
          "state": "Alabama"
        },
        {
          "city": "Casa Grande",
          "state": "Arizona"
        },
        {
          "city": "Chandler",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01073878"
    },
    {
      "nct_id": "NCT01137474",
      "title": "A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes and Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor Blocker",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Type 2 Diabetes"
      ],
      "interventions": [
        {
          "name": "Dapagliflozin",
          "type": "DRUG"
        },
        {
          "name": "Placebo-matching dapagliflozin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "89 Years",
        "sex": "ALL",
        "summary": "18 Years to 89 Years"
      },
      "enrollment_count": 2996,
      "start_date": "2010-07",
      "completion_date": "2013-02",
      "has_results": true,
      "last_update_posted_date": "2017-01-26",
      "last_synced_at": "2026-11-09T22:37:36.857Z",
      "location_count": 164,
      "location_summary": "Birmingham, Alabama • Mobile, Alabama • Ozark, Alabama + 124 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Ozark",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01137474"
    }
  ]
}